<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanaz Memarzadeh, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Don S Dizon, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Uterine sarcomas arise from the myometrium or the connective tissue elements of the endometrium and account for &lt;10 percent of cancers of the uterine corpus [<a href="#rid1">1,2</a>]. These tumors, particularly leiomyosarcoma, often behave aggressively and have a poorer prognosis than endometrioid adenocarcinoma, which is the most common malignancy of the corpus.</p><p>The classification, epidemiology, clinical manifestations, and histopathologic diagnosis of the uterine sarcomas most common in adults (endometrial stromal sarcomas, leiomyosarcoma) are reviewed here. Staging, treatment, and prognosis are discussed separately. Uterine carcinosarcoma, which is no longer classified as a sarcoma, and uterine rhabdomyosarcoma, which typically arises in adolescents, are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">"Treatment and prognosis of uterine leiomyosarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7750.html" rel="external">"Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/7728.html" rel="external">"Rhabdomyosarcoma in childhood and adolescence: Clinical presentation, diagnostic evaluation, and staging"</a> and  <a class="medical medical_review" href="/z/d/html/7721.html" rel="external">"Rhabdomyosarcoma in childhood, adolescence, and adulthood: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The College of American Pathologists  (<a class="graphic graphic_table graphicRef95022" href="/z/d/graphic/95022.html" rel="external">table 1</a>) and the World Health Organization  (<a class="graphic graphic_table graphicRef95023" href="/z/d/graphic/95023.html" rel="external">table 2</a>) have published classification systems for uterine sarcomas based upon the differentiation/growth pattern of the neoplastic cells and their presumed cell of origin [<a href="#rid3">3,4</a>].</p><p>Uterine sarcomas are referred to as "homologous" or "heterologous." Homologous sarcomas only contain elements normally found in uterine tissues (eg, endometrial stroma [connective tissue], smooth muscle, vascular tissue, fibrous tissue) and are the most common type. Endometrial stromal sarcoma and uterine leiomyosarcoma are examples of homologous sarcomas. Heterologous sarcomas contain non-native elements (eg, skeletal muscle, cartilage, bone, fat) and include uterine rhabdomyosarcoma and uterine liposarcoma.</p><p>Historically, uterine carcinosarcoma was considered a type of uterine sarcoma and was termed mixed malignant müllerian tumor or mixed mesodermal sarcoma. However, these neoplasms are now classified as carcinomas since they derive from a monoclonal neoplastic cell, which has more characteristics of epithelial than stromal neoplasms. In addition, the epidemiology, risk factors, and clinical behavior associated with carcinosarcoma suggest a closer relationship to endometrial carcinoma than to sarcoma. (See  <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Uterine sarcomas are rare, in contrast to leiomyoma, which are common (lifetime risk 70 to 80 percent). In one report that corrected for hysterectomy prevalence, the age-adjusted incidence of uterine sarcoma was 2.8 per 100,000 person-years among females ages 30 to 79 years in the United States [<a href="#rid5">5</a>]. The Agency for Healthcare Research and Quality reviewed data from 160 studies to estimate the prevalence of unexpected leiomyosarcoma at the time of surgery for presumed symptomatic leiomyomas and found a range of &lt;1 and up to 13 per 10,000 surgeries [<a href="#rid6">6</a>].</p><p>Most uterine sarcomas occur in patients over age 40; however, they have been diagnosed in patients as young as 20 years old [<a href="#rid7">7,8</a>]. The mean age at diagnosis is approximately 60 years old.</p><p>Black patients have an approximately twofold higher incidence of leiomyosarcomas (but not other types of uterine sarcoma) than White patients [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H3918271682"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The rarity of uterine sarcoma has made it difficult to identify risk factors.</p><p class="headingAnchor" id="H4146831828"><span class="h2">Tamoxifen</span><span class="headingEndMark"> — </span>Long-term use of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (five years or more) appears to be associated with an increased risk for developing uterine sarcoma, but the absolute risk is small [<a href="#rid11">11-13</a>]. In randomized trials in which tamoxifen was used for breast cancer prevention, the incidence of uterine sarcoma in patients assigned to the drug was 17 per 100,000 person-years [<a href="#rid14">14</a>].</p><p>In affected patients, sarcomas present two to five years following the start of therapy and are often at an advanced stage at presentation [<a href="#rid13">13,15</a>]. Multiple histologic subtypes have been identified. (See  <a class="medical medical_review" href="/z/d/html/764.html" rel="external">"Managing the side effects of tamoxifen and aromatase inhibitors"</a>.)</p><p>A relationship between tamoxifen-associated endometrial polyps and uterine sarcoma has not been reported. (See  <a class="medical medical_review" href="/z/d/html/5457.html" rel="external">"Endometrial polyps", section on 'Risk factors and prevention'</a>.)</p><p class="headingAnchor" id="H15672842"><span class="h2">Pelvic radiation</span><span class="headingEndMark"> — </span>A history of pelvic radiation may increase the risk of developing uterine sarcoma [<a href="#rid16">16</a>], but this association appears to be stronger for carcinosarcoma (as discussed above), which is no longer classified as a sarcoma [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">"Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma", section on 'Epidemiology and risk factors'</a>.)</p><p class="headingAnchor" id="H15674059"><span class="h2">Hereditary conditions</span><span class="headingEndMark"> — </span>The following hereditary conditions have been associated with an increased risk of uterine sarcoma, but data are limited:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a rare autosomal dominant syndrome (OMIM #605839) caused by mutations in fumarate hydratase, an enzyme in the Krebs cycle (citric acid cycle), in which affected family members have cutaneous and uterine leiomyomas and an aggressive form of papillary renal cell cancer. An increased risk for uterine sarcomas has also been observed in some populations and often in premenopausal patients but has not been demonstrated in a North American cohort [<a href="#rid18">18,19</a>]. One potential explanation is that patients with this syndrome tend to have very large myomas and may have their uterus removed prior to the development of a sarcoma, given the high hysterectomy rate in the United States. (See  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes", section on 'Hereditary leiomyomatosis and renal cell cancer syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term survivors of childhood retinoblastoma (particularly the hereditary type) are at higher than average risk for a variety of sarcomas, including those arising in the uterus [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas"</a> and  <a class="medical medical_review" href="/z/d/html/107561.html" rel="external">"Retinoblastoma: Treatment and outcome", section on 'Second malignancies'</a>.)</p><p></p><p class="headingAnchor" id="H377210269"><span class="h2">Other</span><span class="headingEndMark"> — </span>Leiomyomas do <strong>not</strong> appear to be the precursor to leiomyosarcomas, with rare exceptions (atypical or cellular variants). (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Do leiomyomas progress to sarcoma?'</a>.)</p><p class="headingAnchor" id="H2684310596"><span class="h1">CLINICAL FINDINGS</span></p><p class="headingAnchor" id="H2709019"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The diagnosis of uterine sarcoma is often made upon routine pathology examination after myomectomy or hysterectomy performed because of presumed leiomyoma. Some cases are diagnosed preoperatively based upon endometrial sampling.</p><p>Signs and symptoms of uterine sarcoma typically include abnormal uterine bleeding, pelvic pain/pressure, and/or a uterine mass, although some patients are asymptomatic. In rare cases, the sarcoma prolapses through the cervix. These clinical findings are the same as those in patients with benign uterine leiomyomas, which affect over 70 percent of patients.</p><p>In one of the largest series of patients with uterine sarcomas, which reported data from a Norwegian registry, the presenting symptoms were [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Postmenopausal bleeding (31 to 46 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Premenopausal abnormal uterine bleeding (27 to 34 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal distension (8 to 17 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal pain (4 to 13 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinary symptoms (1 to 2 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic (1 to 2 percent)</p><p></p><p>Some studies have reported bleeding accompanied by a foul smelling vaginal discharge as part of the clinical presentation [<a href="#rid21">21,22</a>]. Constipation has also been reported, likely due to pelvic pressure.</p><p>In advanced disease, additional clinical manifestations may result from local disease spread and metastases, which do not typically occur with benign leiomyomas, although histologically benign leiomyoma variants also disseminate and must be excluded if widespread disease is found. In one series of over 1000 cases of uterine sarcoma, the distribution of stages  (<a class="graphic graphic_table graphicRef113544" href="/z/d/graphic/113544.html" rel="external">table 3</a>) at presentation was stage I (60 percent), stage II and III (16 percent), and stage IV (22 percent) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3188.html" rel="external">"Treatment and prognosis of uterine leiomyosarcoma"</a> and  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma"</a>.)</p><p class="headingAnchor" id="H2223248430"><span class="h2">Physical examination and ultrasound imaging</span><span class="headingEndMark"> — </span>The findings on physical examination and imaging are similar to those for benign uterine leiomyomas, as well as for atypical leiomyoma variants. On ultrasound, both sarcomas and leiomyomas are focal masses within the uterus. Features suggestive of sarcoma include mixed echogenic and poor echogenic parts; central necrosis; and color Doppler findings of irregular vessel distribution, low impedance to flow, and high peak systolic velocity. However, many of these characteristics may also be found in benign leiomyomas. Findings on ultrasound and magnetic resonance imaging are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Imaging'</a>.)</p><p>On pelvic examination, the uterus is often enlarged but may be normal in size. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Signs and symptoms'</a>.)</p><p class="headingAnchor" id="H2870871785"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Small case series have reported elevated levels of serum cancer antigen 125 and a subtype of lactate dehydrogenase (isozyme type 3) in patients with uterine sarcoma [<a href="#rid23">23-25</a>].</p><p class="headingAnchor" id="H3430210181"><span class="h1">WHEN TO SUSPECT UTERINE SARCOMA</span><span class="headingEndMark"> — </span>In our practice, we consider the diagnosis of uterine sarcoma in postmenopausal patients with presumed uterine leiomyomas who have symptoms sufficiently bothersome to consider hysterectomy; however, even in this group, the incidence of sarcoma is approximately 0.2 percent [<a href="#rid26">26-35</a>]. In premenopausal patients with presumed uterine leiomyomas, we consider the diagnosis of uterine sarcoma if bleeding is disproportionate to uterine size and the patient reports significant pain. The clinical approach to differentiating uterine leiomyomas from uterine sarcomas is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Presumed benign leiomyomas'</a>.)</p><p>Although it is commonly believed that sarcoma should be suspected in patients with a "rapidly growing" uterus or leiomyoma (ie, doubling in size over a period of three to six months or increasing by six weeks gestational size within one year [<a href="#rid26">26</a>]), the data do not support an increased risk of malignant neoplasm in such patients or in those with large uterine size (in excess of 20 gestational weeks). (See  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Rapidly growing uterine mass in premenopausal patients'</a> and  <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">"Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Large or solitary uterine mass'</a>.)</p><p class="headingAnchor" id="H3370553370"><span class="h2">Tissue sampling</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometrial biopsy</strong> – Endometrial biopsy should be performed in patients with risk factors, symptoms, or findings suggestive of a uterine malignant neoplasm, as described in the table  (<a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Endometrial sampling yields a diagnosis of uterine sarcoma in some affected patients, but there are few data regarding the sensitivity of this test [<a href="#rid36">36,37</a>]. In the largest study, which included 21 patients with a leiomyosarcoma, endometrial stromal sarcoma, or another sarcoma, preoperative endometrial sampling correctly identified the histology as a sarcoma in 13/21 cases (62 percent), suggested another diagnosis in 3 cases (2 adenocarcinoma, 1 carcinosarcoma), and was negative in 5 cases [<a href="#rid38">38</a>]. Curettage and endometrial biopsy appeared to have similar sensitivity. In a smaller series of eight patients, sensitivity of endometrial sampling for diagnosis of sarcoma was 38 percent [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transvaginal biopsy of a prolapsed mass</strong> – Biopsy of a prolapsed mass may show that the mass is a sarcoma; however, biopsy prior to excision is not commonly performed because almost all prolapsed masses are benign (fibroid or a cervical or endometrial polyp). Excision accomplishes two goals (ie, diagnosis and relief of symptoms) with a single procedure. Biopsy before excision is indicated only if the appearance of the mass is not consistent with a common benign lesion. Leiomyomas tend to be white and hard, whereas sarcomas are more fleshy and can be friable.<strong> </strong>However, assuming a prolapsed mass is benign and removing it vaginally does not worsen the prognosis if it is actually a sarcoma. (See  <a class="medical medical_review" href="/z/d/html/3295.html" rel="external">"Uterine fibroids (leiomyomas): Prolapsed fibroids", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transabdominal biopsy</strong> – Use of minimally invasive needle biopsy of a uterine mass (guided by pelvic imaging or laparoscopy) has been proposed to diagnose sarcoma but is investigational [<a href="#rid39">39</a>]. Limitations of this method are that the accurate diagnosis of sarcoma requires sampling of multiple sites and that the procedure may spill malignant cells within the peritoneal cavity.</p><p></p><p class="headingAnchor" id="H2708853"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H451133745"><span class="h2">Criteria</span><span class="headingEndMark"> — </span>The diagnosis of uterine sarcoma is based upon histologic examination. Examination of multiple sites in the mass is often necessary [<a href="#rid40">40</a>]. Features of the gross appearance of the mass, including the color, consistency, and variegation of the incised surface, can help guide sites for tissue sampling for microscopic examination.</p><p>The three most important histologic criteria for the diagnosis of uterine sarcomas are mitotic index, cellular atypia, and geographic areas of coagulative necrosis separated from viable neoplasm [<a href="#rid41">41,42</a>]. Cellularity and type (eg, myxoid or epithelioid) are also utilized. The more features exhibited by the lesion, the more likely it is to have clinically aggressive behavior [<a href="#rid41">41,42</a>]. (See <a class="local">'Histopathology'</a> below.)</p><p>There is no reliable way to determine if a leiomyoma might be a leiomyosarcoma prior to surgical removal and review by the pathologist.</p><p class="headingAnchor" id="H1300102903"><span class="h2">Histopathology</span></p><p class="headingAnchor" id="H1727726696"><span class="h3">Endometrial stromal and related tumors</span><span class="headingEndMark"> — </span>Endometrial stromal sarcomas (ESS) are uterine mesenchymal neoplasms with malignant potential. The gross appearance often reveals a polypoid mass that can invade through blood vessels or lymphatics. Historically, they were characterized as either low-grade or high-grade ESS. The World Health Organization classification system (5<sup>th</sup> edition) recognizes the following tumor types under the category "endometrial stromal and related tumors"  (<a class="graphic graphic_table graphicRef95023" href="/z/d/graphic/95023.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial stromal nodule (ESN)</p><p class="bulletIndent1"><span class="glyph">●</span>Low-grade endometrial stromal sarcoma (LG-ESS)</p><p class="bulletIndent1"><span class="glyph">●</span>High-grade endometrial stromal sarcoma (HG-ESS)</p><p class="bulletIndent1"><span class="glyph">●</span>Undifferentiated uterine sarcoma (UUS)</p><p></p><p>Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is no longer considered a true endometrial stromal tumor and is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'UTROSCT'</a>.)</p><p>The terminology and classification system for ESS and related tumors have been changed several times. An understanding of the shifts in nomenclature is essential to being able to interpret prior studies in relation to the new designations. Terminology, histopathology, and molecular characteristics are reviewed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'Classification'</a> and  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'Histopathology'</a> and  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'Molecular characteristics'</a>.)</p><p class="headingAnchor" id="H2540614004"><span class="h3">Leiomyosarcoma</span><span class="headingEndMark"> — </span>Leiomyosarcomas are typically large (&gt;10 cm), yellow or tan solitary masses with soft, fleshy cut surfaces with areas of hemorrhage and necrosis [<a href="#rid43">43</a>]. The mass may bulge into the uterine cavity, but the epicenter is in the myometrium.</p><p>Leiomyosarcomas typically (though not always) have prominent cellular atypia, abundant mitoses (≥10 per 10 high-power fields), and areas of coagulative necrosis  (<a class="graphic graphic_picture graphicRef70835 graphicRef53942" href="/z/d/graphic/70835.html" rel="external">picture 1A-B</a>). Epithelial neoplasms have a clearly defined behavior (invasion) that indicates metastatic potential. Because smooth muscle neoplasms arise in the stroma (do not live in a compartment), they are more difficult to distinguish as benign (without metastatic potential) or malignant (with metastatic potential). Cellular atypia, mitosis, and "coagulative necrosis" are known as the Stanford criteria (originally described by the Stanford group). In the largest retrospective study, which resulted in the development of these criteria, the presence of two of the three features indicated a risk of metastatic spread of &gt;10 percent [<a href="#rid41">41</a>]. However, opinions vary as to the exact level of mitotic activity required for diagnosis of sarcoma [<a href="#rid44">44</a>]. Other common features, which are not diagnostic in isolation but may be used in borderline cases, are hypercellularity and infiltrative border [<a href="#rid44">44</a>].</p><p>There are three main subtypes of leiomyosarcoma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spindle cell (conventional) tumors</strong> – Spindle cell tumors are characterized by two or more of the following: tumor cell necrosis, marked cytological atypia, and ≥10 mitoses per 10 high-power fields [<a href="#rid3">3</a>]. Rarely, spindle leiomyosarcoma may arise from a background of leiomyoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epithelioid leiomyosarcoma</strong> – Epithelioid leiomyosarcoma is characterized by round to polygonal cells with abundant eosinophilic or clear cytoplasm [<a href="#rid15">15</a>]. Epithelioid leiomyomas with atypia and ≥5 mitoses per 10 high-power fields qualify as leiomyosarcoma. The absence of coagulative necrosis does not confirm benign behavior in these neoplasms. The clinical behavior is not well established for large (&gt;6 cm) epithelioid smooth muscle neoplasms with moderate mitotic activity (two to four mitoses per 10 high-power fields). Such neoplasms should be classified as epithelioid smooth muscle tumors of uncertain malignant potential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myxoid leiomyosarcoma</strong> – Myxoid leiomyosarcoma does not fit well into the Stanford scheme and is classified separately. The myxoid appearance may obscure the smooth muscle differentiation, the extent of nuclear pleomorphism, and the true number of mitotic figures. Although myxoid leiomyomas and smooth muscle neoplasms with prominent myxoid features must be thoroughly evaluated, particularly for mitosis because, despite their apparently bland features, these neoplasms may behave in a highly malignant manner [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H621432844"><span class="h3">Other</span><span class="headingEndMark"> — </span>Less common histologies include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed endometrial stromal and smooth muscle tumor</strong> – These neoplasms, also referred to as stromomyomas, are defined as having at least 30 percent each of endometrial stromal and smooth muscle components [<a href="#rid46">46</a>]. There are few data regarding these lesions [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenosarcoma</strong> – Adenosarcoma of the uterus is a rare mixed neoplasm in which a benign epithelial component is mixed with a malignant stromal (ie, sarcomatous) element  (<a class="graphic graphic_picture graphicRef70818 graphicRef50860" href="/z/d/graphic/70818.html" rel="external">picture 2A-B</a>) [<a href="#rid48">48</a>]. A variant, adenosarcoma with sarcomatous overgrowth, appears to have a worse prognosis, similar to carcinosarcoma [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/16903.html" rel="external">"Endometrial stromal sarcomas, related tumors, and uterine adenosarcoma", section on 'Adenosarcoma'</a>.)</p><p></p><p class="headingAnchor" id="H1976719733"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H16014619"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15422.html" rel="external">"Patient education: Uterine cancer (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/866.html" rel="external">"Patient education: Endometrial cancer diagnosis, staging, and surgical treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Uterine sarcomas are rare, in contrast to uterine leiomyomas, which are common (lifetime risk 70 to 80 percent). In one report that corrected for hysterectomy prevalence, the age-adjusted incidence of uterine sarcoma was 2.8 per 100,000 person-years among females ages 30 to 79 years in the United States. The mean age at diagnosis is approximately 60 years old. Black females have an approximately twofold higher incidence of leiomyosarcomas (but not other types of uterine sarcoma) than White females. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – The College of American Pathologists  (<a class="graphic graphic_table graphicRef95022" href="/z/d/graphic/95022.html" rel="external">table 1</a>) and the World Health Organization  (<a class="graphic graphic_table graphicRef95023" href="/z/d/graphic/95023.html" rel="external">table 2</a>) have published classification systems for uterine sarcomas based upon the differentiation/growth pattern of the neoplastic cells and their presumed cell of origin. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Endometrial stromal sarcomas and leiomyosarcomas are the two most common types of uterine sarcoma in adult patients. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for uterine sarcoma include long-term use of <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (five years or more) and pelvic radiation. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome and childhood retinoblastoma are genetic conditions associated with uterine sarcoma. Having a leiomyoma is not a risk factor for developing a sarcoma, with rare exceptions. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical findings</strong> – Signs and symptoms of uterine sarcoma typically include abnormal uterine bleeding, pelvic pain/pressure, and/or a uterine mass, although some patients are asymptomatic. The uterus is often enlarged but may be of normal size. These clinical findings are the same as those in patients with benign uterine leiomyomas, which affect over 70 percent of patients. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Physical examination and ultrasound imaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect uterine sarcoma</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although it is commonly believed that sarcoma should be suspected in patients with a "rapidly growing" uterus or leiomyoma (ie, doubling in size over a period of three to six months or increasing by six weeks gestational size within one year), the data do not support an increased risk of malignant neoplasm in such patients or in those with large uterine size (&gt;20 gestational weeks). (See <a class="local">'When to suspect uterine sarcoma'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In our practice, we consider the diagnosis of uterine sarcoma in postmenopausal patients with presumed uterine leiomyomas who have symptoms sufficiently bothersome to consider hysterectomy; however, even in this group, the incidence of sarcoma is approximately 0.2 percent. In premenopausal patients with presumed uterine leiomyomas, we consider the diagnosis if bleeding is disproportionate to uterine size and the patient reports significant pain. Endometrial biopsy may yield an accurate diagnosis in some patients, but a negative biopsy does not rule out the disease. (See <a class="local">'When to suspect uterine sarcoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of uterine sarcoma is based upon histologic examination of a tissue sample  (<a class="graphic graphic_picture graphicRef70835 graphicRef53942 graphicRef70818 graphicRef50860" href="/z/d/graphic/70835.html" rel="external">picture 1A-B, 2A-B</a>). The diagnosis is often unexpected and made upon routine pathology examination after myomectomy or hysterectomy performed because of presumed leiomyoma. There is no reliable way to determine if a leiomyoma might be a leiomyosarcoma prior to surgical removal and review by the pathologist. The prevalence of unexpected leiomyosarcoma at the time of surgery for presumed symptomatic leiomyomas ranges from &lt;1 and up to 13 per 10,000 surgeries. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="headingAnchor" id="H469778725"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Arno Mundt, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997; 33:907.</a></li><li><a class="nounderline abstract_t">Tropé CG, Abeler VM, Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol 2012; 51:694.</a></li><li class="breakAll">WHO Classification of Tumours Editorial Board. Female Genital Tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2022 Dec 19]. (WHO classification of tumours series, 5th ed.; vol. 4). Available from: https://tumourclassification.iarc.who.int/.</li><li class="breakAll">htpps://documents.cap.org/protocols/Uterus.Sarc_4.4.0.0.REL_CAPCP.pdf (Accessed on December 19, 2022).</li><li><a class="nounderline abstract_t">Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. J Clin Oncol 2019; 37:1895.</a></li><li class="breakAll">Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of Uterine Fibroids. Comparative Effectiveness Review No. 195.  Rockville, MD: Agency for Healthcare Research and Quality; December 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-195-uterine-fibroids-final-revision.pdf (Accessed on October 04, 2019).</li><li><a class="nounderline abstract_t">Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966; 19:755.</a></li><li><a class="nounderline abstract_t">Ricci S, Stone RL, Fader AN. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation. Gynecol Oncol 2017; 145:208.</a></li><li><a class="nounderline abstract_t">Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93:204.</a></li><li><a class="nounderline abstract_t">Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003; 98:176.</a></li><li><a class="nounderline abstract_t">Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97:855.</a></li><li><a class="nounderline abstract_t">Yildirim Y, Inal MM, Sanci M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases. Int J Gynecol Cancer 2005; 15:1239.</a></li><li><a class="nounderline abstract_t">Wysowski DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002; 346:1832.</a></li><li><a class="nounderline abstract_t">Wickerham DL, Fisher B, Wolmark N, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20:2758.</a></li><li><a class="nounderline abstract_t">Moinfar F, Azodi M, Tavassoli FA. Uterine sarcomas. Pathology 2007; 39:55.</a></li><li><a class="nounderline abstract_t">Mark RJ, Poen J, Tran LM, et al. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol 1996; 19:59.</a></li><li><a class="nounderline abstract_t">Meredith RF, Eisert DR, Kaka Z, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer 1986; 58:2003.</a></li><li><a class="nounderline abstract_t">Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001; 98:3387.</a></li><li><a class="nounderline abstract_t">Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003; 73:95.</a></li><li><a class="nounderline abstract_t">Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101:581.</a></li><li><a class="nounderline abstract_t">Liao Q, Wang J, Han J. [Clinical and pathological analysis on 106 cases with uterine sarcoma]. Zhonghua Fu Chan Ke Za Zhi 2001; 36:104.</a></li><li><a class="nounderline abstract_t">Schwartz Z, Dgani R, Lancet M, Kessler I. Uterine sarcoma in Israel: a study of 104 cases. Gynecol Oncol 1985; 20:354.</a></li><li><a class="nounderline abstract_t">Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. Int J Gynecol Cancer 2002; 12:354.</a></li><li><a class="nounderline abstract_t">Huang GS, Chiu LG, Gebb JS, et al. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007; 107:513.</a></li><li><a class="nounderline abstract_t">Hoskins PJ, Le N. Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 2008; 18:1200.</a></li><li><a class="nounderline abstract_t">Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83:414.</a></li><li><a class="nounderline abstract_t">Leung F, Terzibachian JJ, Gay C, et al. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?]. Gynecol Obstet Fertil 2009; 37:109.</a></li><li><a class="nounderline abstract_t">Leibsohn S, d'Ablaing G, Mishell DR Jr, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990; 162:968.</a></li><li><a class="nounderline abstract_t">Takamizawa S, Minakami H, Usui R, et al. Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas. Gynecol Obstet Invest 1999; 48:193.</a></li><li><a class="nounderline abstract_t">Leung F, Terzibachian JJ. Re: "The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma". Gynecol Oncol 2012; 124:172.</a></li><li><a class="nounderline abstract_t">Durand-Réville M, Dufour P, Vinatier D, et al. [Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports]. J Gynecol Obstet Biol Reprod (Paris) 1996; 25:710.</a></li><li><a class="nounderline abstract_t">Seidman MA, Oduyebo T, Muto MG, et al. Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms. PLoS One 2012; 7:e50058.</a></li><li><a class="nounderline abstract_t">Theben JU, Schellong AR, Altgassen C, et al. Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): an analysis of 1,584 LASH cases. Arch Gynecol Obstet 2013; 287:455.</a></li><li><a class="nounderline abstract_t">Sinha R, Hegde A, Mahajan C, et al. Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy? J Minim Invasive Gynecol 2008; 15:292.</a></li><li><a class="nounderline abstract_t">Hagemann IS, Hagemann AR, LiVolsi VA, et al. Risk of occult malignancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol 2011; 30:476.</a></li><li><a class="nounderline abstract_t">Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67:33.</a></li><li><a class="nounderline abstract_t">Jin Y, Pan L, Wang X, et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer 2010; 20:1535.</a></li><li><a class="nounderline abstract_t">Bansal N, Herzog TJ, Burke W, et al. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008; 110:43.</a></li><li><a class="nounderline abstract_t">Kawamura N, Ichimura T, Ito F, et al. Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma. Cancer 2002; 94:1713.</a></li><li><a class="nounderline abstract_t">Quade BJ. Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions. Curr Opin Obstet Gynecol 1995; 7:35.</a></li><li><a class="nounderline abstract_t">Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994; 18:535.</a></li><li><a class="nounderline abstract_t">Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 2004; 40:97.</a></li><li class="breakAll">Kurma RJ. Pathology of the Female Genital Tract, 4th, Springer Verlag, New York  p.499.</li><li class="breakAll">Silverberg SG, Kurman RJ. Tumors of the uterine corpus and gestational trophoblastic disease. In: Atlas of Tumor Pathology - Armed Forces Institute of Pathology, electronic fascicle version 2., Washington DC.</li><li><a class="nounderline abstract_t">Karpathiou G, Sivridis E, Giatromanolaki A. Myxoid leiomyosarcoma of the uterus: a diagnostic challenge. Eur J Gynaecol Oncol 2010; 31:446.</a></li><li><a class="nounderline abstract_t">Oliva E, Clement PB, Young RH, Scully RE. Mixed endometrial stromal and smooth muscle tumors of the uterus: a clinicopathologic study of 15 cases. Am J Surg Pathol 1998; 22:997.</a></li><li><a class="nounderline abstract_t">Kir G, Gurbuz A, Karateke A, Dayicioglu V. Stromomyomas of the uterus-- importance of total circumferential evaluation of the margin. Eur J Gynaecol Oncol 2004; 25:489.</a></li><li><a class="nounderline abstract_t">Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990; 21:363.</a></li><li><a class="nounderline abstract_t">Krivak TC, Seidman JD, McBroom JW, et al. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001; 83:89.</a></li></ol></div><div id="topicVersionRevision">Topic 3211 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291814" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22793037" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and treatment of sarcoma of the uterus. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22793037" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diagnosis and treatment of sarcoma of the uterus. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22793037" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and treatment of sarcoma of the uterus. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31116674" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31116674" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5939046" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28209496" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15047237" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12833470" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11336777" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tamoxifen treatment and gynecologic side effects: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16343223" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050351" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Uterine sarcoma associated with tamoxifen use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12039943" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of tamoxifen and uterine sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17365823" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Uterine sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554038" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3756818" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An excess of uterine sarcomas after pelvic irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11248088" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inherited susceptibility to uterine leiomyomas and renal cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12772087" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19351917" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cause-specific mortality in long-term survivors of retinoblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11783345" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Clinical and pathological analysis on 106 cases with uterine sarcoma].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2982707" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Uterine sarcoma in Israel: a study of 104 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12144683" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935762" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217961" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127535" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19200764" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327466" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10545745" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk of complications and uterine malignancies in women undergoing hysterectomy for presumed benign leiomyomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21955481" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Re: "The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8991905" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Uterine leiomyosarcomas: a surprising pathology. Review of the literature. Six case reports].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23189178" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Peritoneal dissemination complicating morcellation of uterine mesenchymal neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053310" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Unexpected malignancies after laparoscopic-assisted supracervical hysterectomies (LASH): an analysis of 1,584 LASH cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18439500" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804400" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk of occult malignancy in morcellated hysterectomy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459493" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21370596" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18445505" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The utility of preoperative endometrial sampling for the detection of uterine sarcomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920533" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7742513" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pathology, cytogenetics and molecular biology of uterine leiomyomas and other smooth muscle lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179071" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101043" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101043" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15101043" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20882892" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Myxoid leiomyosarcoma of the uterus: a diagnostic challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9706980" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mixed endometrial stromal and smooth muscle tumors of the uterus: a clinicopathologic study of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15285311" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Stromomyomas of the uterus-- importance of total circumferential evaluation of the margin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2156771" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585418" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
